KBI Biopharma Inc.

To date, KBI has conducted over 130 successful protein, peptide, and vaccine formulation development programs. KBI's approach to formulation development is based on the strategic pairing of two complementary scientific disciplines: Establishing a comprehensive understanding of the thermal, physical, chemic...

KBI Biopharma has extensive experience developing purification processes for a wide variety of biotherapeutics, including: -Monoclonal antibodies-Bispecific antibodies -Enzymes -Fc fusion proteins -PEGylated proteins -Complex glycoproteins KBI supports 40+ annual programs ranging from FIH (First-in-Huma...

KBI Biopharma offers industry-leading cell line development (CLD) services across both mammalian and microbial platforms, tailored to accelerate biotherapeutic development from gene to GMP.

For mammalian expression, KBI deploys a range of platforms including CHO-M Selexis SUREtechnology™, CHO-...

KBI Biopharma delivers end-to-end process development services for both mammalian and microbial-based biologics, enabling efficient scale-up and robust transfer to cGMP manufacturing.

Our team supports the full development cycle, from early-stage feasibility and small-scale protein production ...

When your program demands precise answers, our over two decades of experience tackling complex challenges deliver rapid, dependable results powered by profound scientific expertise.

Your analytical challenges demand comprehensive lifecycle support with customized solutions. Whether add...

An ideal therapeutic protein “factory” creates a pure target product with high titers from the start, which can minimize development risk, timelines, and cost. E. coli has long been implemented as a therapeutic protein factory due to its simplicity, tractability, and wealth of information characterizing the microbe.

While common E. coli expression strains alter as many as five genes to improve one aspect of recombinant protein expression, KBI has created a platform E. coli with about 1,000 genes altered and roughly 1 Mbp of DNA removed. The result is a PURE, efficient platform expression strain—PUREcoli™.